BDX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

5.15B

-0.31%

2.811

-18.04%

5.54B

+4.99%

3.369

+0.56%

5.74B

+4.13%

3.971

+7.91%

Estimates Revision

The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2026, with the revenue forecasts being adjusted by -1.37% over the past three months. During the same period, the stock price has changed by 8.93%.

Revenue Estimates for FY2026

Revise Downward

-1.37%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+0.32%

In Past 3 Month

Stock Price

Go Up

+8.93%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 193.71 USD with a low forecast of 183.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

183.00

Averages

193.71

High

210.00

Current: 0.000

Low

183.00

Averages

193.71

High

210.00

Stifel

NULL

Buy

maintain

$210 -> $215

2026-01-07

New

Reason

Stifel

Price Target

$210 -> $215

2026-01-07

New

maintain

NULL

Buy

Reason

Stifel raised the firm's price target on Becton Dickinson (BDX) to $215 from $210 and keeps a Buy rating on the shares. The firm, which argues that the 2026 setup is constructive for large-cap MedTech following 2025 pressures, adjusted targets among its coverage and highlights Boston Scientific (BSX), Edwards Lifesciences (EW), and Solventum (SOLV) as its three top ideas entering the year.

BofA

Travis Steed

Neutral

maintain

$190 -> $207

2026-01-05

New

Reason

BofA

Travis Steed

Price Target

$190 -> $207

2026-01-05

New

maintain

Neutral

Reason

BofA analyst Travis Steed raised the firm's price target on Becton Dickinson to $207 from $190 and keeps a Neutral rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.

RBC Capital

Sector Perform

maintain

$202 -> $210

2025-12-17

Reason

RBC Capital

Price Target

$202 -> $210

2025-12-17

maintain

Sector Perform

Reason

RBC Capital raised the firm's price target on Becton Dickinson to $210 from $202 and keeps a Sector Perform rating on the shares as part of a broader research note previewing 2026 for Medical Supplies & Devices. The firm anticipates a year of positive momentum as sector fundamentals are solidly intact driven by the aging demographics, growing global healthcare access, and differentiated innovation, the analyst tells investors in a research note. For the company, RBC believes it is positioned to grow mid-single-digits due to its strong durable core with high recurring revenue.

Morgan Stanley

Patrick Wood

Overweight

maintain

$197 -> $210

2025-12-02

Reason

Morgan Stanley

Patrick Wood

Price Target

$197 -> $210

2025-12-02

maintain

Overweight

Reason

Morgan Stanley analyst Patrick Wood raised the firm's price target on Becton Dickinson to $210 from $197 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.

Stifel

Buy

downgrade

$224 -> $210

2025-11-07

Reason

Stifel

Price Target

$224 -> $210

2025-11-07

downgrade

Buy

Reason

Stifel lowered the firm's price target on Becton Dickinson to $210 from $224 and keeps a Buy rating on the shares following the company's Q4 report and below-consensus FY26 guidance. This "reset" potentially offers a "conservative setup," the analyst tells investors.

RBC Capital

Shagun Singh

Sector Perform

downgrade

$211 -> $202

2025-11-07

Reason

RBC Capital

Shagun Singh

Price Target

$211 -> $202

2025-11-07

downgrade

Sector Perform

Reason

RBC Capital analyst Shagun Singh lowered the firm's price target on Becton Dickinson to $202 from $211 and keeps a Sector Perform rating on the shares. The company's Q4 results came largely in-line with expectations as it issued preliminary results on 10/15 but delivered a 1% surprise on the bottom-line, the analyst tells investors in a research note. Becton Dickinson's FY26 guidance at low single digit growth was somewhat below consensus due to ongoing headwinds around Alaris comps, China, and vaccine reductions however, the firm added.

Valuation Metrics

The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 13.05, compared to its 5-year average forward P/E of 18.69. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.69

Current PE

13.05

Overvalued PE

21.89

Undervalued PE

15.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

14.79

Current EV/EBITDA

11.40

Overvalued EV/EBITDA

16.94

Undervalued EV/EBITDA

12.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.39

Current PS

2.47

Overvalued PS

3.90

Undervalued PS

2.88

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 956.9% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BDX News & Events

Events Timeline

No data

News

8.5

01-07PRnewswire

Waters Corporation Investigated for Merger with BDX, Shareholders to Own 60.8% Post-Transaction

8.5

01-06Benzinga

BD and Waters Merger Expected to Boost EPS by $0.10 in 2026

8.0

01-06NASDAQ.COM

Mastercard Boosts Dividend by 14%, Optimistic Future Outlook

People Also Watch

Frequently Asked Questions

What is Becton Dickinson and Co (BDX) stock price today?

The current price of BDX is 205.97 USD — it has increased 0.39 % in the last trading day.

What is Becton Dickinson and Co (BDX)'s business?

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

What is the price predicton of BDX Stock?

What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?

Becton Dickinson and Co revenue for the last quarter amounts to 5.89B USD, increased 8.35 % YoY.

What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?

Becton Dickinson and Co. EPS for the last quarter amounts to 1.71 USD, increased 24.82 % YoY.

What changes have occurred in the market's expectations for Becton Dickinson and Co (BDX)'s fundamentals?

How many employees does Becton Dickinson and Co (BDX). have?

Becton Dickinson and Co (BDX) has 72000 emplpoyees as of January 09 2026.

What is Becton Dickinson and Co (BDX) market cap?

Today BDX has the market capitalization of 58.46B USD.